BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diagnostics (Basel)
Hauptverfasser: Bilbao-Sieyro, Cristina, Rodríguez-Medina, Carlos, Florido, Yanira, Stuckey, Ruth, Sáez, María Nieves, Sánchez-Sosa, Santiago, González Martín, Jesús María, Santana, Guillermo, González-Pérez, Elena, Cruz-Cruz, Naylén, Fernández, Rosa, Molero Labarta, Teresa, Gomez-Casares, María Teresa
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7762084/
https://ncbi.nlm.nih.gov/pubmed/33291851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10121048
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge